Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study

Дизайн исследования терапии бактериофагами при легочном заболевании, вызванном нетуберкулезными микобактериями, у пациентов с муковисцидозом: исследование POSTSTAMP
Graham F. Hatfull, Charles L. Daley, Emily DiMango, Amalia Magaret, Deborah Jacobs‐Sera, Noah Lechtzin, Keira A. Cohen, Jerry A. Nick, Manu Jain, Raksha Jain, Stacey L. Martiniano, Jane E. Gross, Silvia M. Caceres, Katie R. Poch, Valerie K. Lovell, Brian E. Vestal, N. Rysavy, Vinicius Calado de Moura, Jennifer J Gilick, Kenneth C. Malcolm, Jessica Pacheco, Anita G. Amin, Delphi Chatterjee, Shannon H. Kasperbauer, Emily Armantrout, Allison Keck, Jill M. VanDalfsen, Nikita A. Midamba, Claire Chapdu, Antao Gao, Jane E Hill, Krista G. Freeman, Madison Cristinziano, Carlos A. Guerrero-Bustamante, Michael J․ Lauer, Maggie Viland, G․ Marty Solomon, Carmen Reyes, Douglas J․ Conrad, Silvia Delgado Villalta, Noah Lechtzin, Rebecca E․ Cagnina, Lindsay J․ Caverly, Brian P․ O'Sullivan, Emily A․ DiMango, Jennifer L․ Goralski, Charles R․ Esther, Karen S․ McCoy, Joseph M․ Pilewski, Zachary L․ Weintraub, Ronald L․ Gibson, Kathleen J․ Ramos
2025-04-12

Mycobacterium abscessusPOSTSTAMP studybacteriophage therapycystic fibrosispulmonary disease
Bacteriophages (phages) are viruses that selectively infect bacteria and have been utilized to treat Mycobacterium abscessus (Mab) with varying success. The POSTSTAMP study is an ongoing, multi-site phage therapy protocol for treatment-refractory pulmonary Mab disease in people with cystic fibrosis (pwCF). Participants (n = 10) are prospectively assessed while utilizing FDA investigational new drug (IND) approval for compassionate use. Participants are >6 years old, able to produce sputum, have been treated with guideline-based antibiotic therapy (GBT) for >12 months without culture conversion, and are currently receiving GBT with at least 3 and ≥ 80 % positive Mab cultures in the prior year. At enrollment, an isolate is assessed for the availability of lytic phage(s). Open-label phage therapy consists of 1 or 2 phages administered intravenously twice daily for 52 weeks. Participants without a phage match will be followed on GBT as a comparison group. Follow-up visits will occur monthly, with one follow-up visit at completion and intermittent visits for a year after phage therapy. Efficacy will be assessed by culture, standard clinical measures and a patient-reported quality-of-life instrument. Frequency of Mab detection 12 months prior to treatment will be compared with the 12-month period beginning 6 months after treatment initiation. Individual-level tests of difference in percent positive cultures within subjects will be used to identify "responders". Collectively and including all persons, a mixed-effect model will be used to test for a difference in frequency of Mab detection following treatment or without treatment. The trial will also test for markers of treatment failure and pathogen adaptation in participants who did not achieve microbiological response, and will monitor for safety and tolerance.
1
POSTSTAMP is an ongoing multisite study evaluating compassionate-use bacteriophage therapy for treatment-refractory pulmonary Mycobacterium abscessus disease in people with cystic fibrosis.
2
Participants receive one or two matched lytic phages intravenously twice daily for 52 weeks; individuals without an available phage match are followed on antibiotic therapy as a comparison group.
3
The protocol enrolls 10 participants older than 6 years who remain culture-positive despite more than 12 months of guideline-based antibiotic therapy.
4
The study will evaluate safety and tolerance and investigate treatment-failure markers and pathogen adaptation in participants without microbiological response.
5
Treatment efficacy will be assessed using sputum culture frequency, standard clinical measures, and patient-reported quality of life, with microbiological responses compared before and after therapy.

treatment-refractory pulmonary Mycobacterium abscessus disease in people with cystic fibrosis

the efficacy, safety, tolerance, microbiological response, treatment-failure markers, and pathogen adaptation associated with intravenous bacteriophage therapy

Publication Details
Publication Date
2025-04-12
Journal
Publisher
ISSN
Cited by
4
Access Type
Author Information
Authors
Graham F. Hatfull
Charles L. Daley
Emily DiMango
Amalia Magaret
Deborah Jacobs‐Sera
Noah Lechtzin
Keira A. Cohen
Jerry A. Nick
Manu Jain
Raksha Jain
Stacey L. Martiniano
Jane E. Gross
Silvia M. Caceres
Katie R. Poch
Valerie K. Lovell
Brian E. Vestal
N. Rysavy
Vinicius Calado de Moura
Jennifer J Gilick
Kenneth C. Malcolm
Jessica Pacheco
Anita G. Amin
Delphi Chatterjee
Shannon H. Kasperbauer
Emily Armantrout
Allison Keck
Jill M. VanDalfsen
Nikita A. Midamba
Claire Chapdu
Antao Gao
Jane E Hill
Krista G. Freeman
Madison Cristinziano
Carlos A. Guerrero-Bustamante
Michael J․ Lauer
Maggie Viland
G․ Marty Solomon
Carmen Reyes
Douglas J․ Conrad
Silvia Delgado Villalta
Noah Lechtzin
Rebecca E․ Cagnina
Lindsay J․ Caverly
Brian P․ O'Sullivan
Emily A․ DiMango
Jennifer L․ Goralski
Charles R․ Esther
Karen S․ McCoy
Joseph M․ Pilewski
Zachary L․ Weintraub
Ronald L․ Gibson
Kathleen J․ Ramos
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%